Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8721196 | Clinical Immunology | 2018 | 35 Pages |
Abstract
Hydroxychloroquine is widely used for autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. Although B cells contribute to the pathogenesis of these diseases, the action of hydroxychloroquine on B cells remains unclear. Here we examined the effects of hydroxychloroquine on functions of B cell subsets. Hydroxychloroquine efficiently inhibited the mammalian target of rapamycin complex 1, differentiation of CD19+IgDâCD27+ class-switched memory B cells to plasmablasts and their IgG production, under stimulation with CpG, a Toll-like receptor (TLR)-9 ligand. Hydroxychloroquine also inhibited CpG-induced production of interleukin-6 and tumor necrosis factor-α in B cell subsets. Taken together, hydroxychloroquine markedly suppresses the TLR9-mediated human B cell functions during inflammatory processes. Based on our results, we believe that hydroxychloroquine can be beneficial in the treatment of B cell-mediated autoimmune diseases.
Keywords
LPSPBMCPlasmablastdsDNACFSECpGmTORC1double-stranded DNApDCsTLRsRheumatoid arthritisimmunoglobulin interferonIFNcluster of differentiationperipheral blood mononuclear cellsplasmacytoid dendritic cellsCytosine-phosphate-GuanineSystemic lupus erythematosusSLElipopolysaccharideMammalian target of rapamycin complex 1hydroxychloroquinecarboxyfluorescein succinimidyl esterToll-like receptorsToll-like receptor 9
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Masataka Torigoe, Kei Sakata, Akina Ishii, Shigeru Iwata, Shingo Nakayamada, Yoshiya Tanaka,